Baclofen for the Treatment of Cocaine Dependence - 1

Phase 2CompletedNCT00082485

National Institute on Drug Abuse (NIDA)160 enrolled

Overview

The purpose of this study is to assess the efficacy and safety of baclofen for the treatment of cocaine dependence.

Double-blind, placebo-controlled, parallel design trial of baclofen for the treatment of cocaine dependence

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

160

Conditions

Cocaine-Related Disorders

Interventions

BaclofenDRUG

Dose escalation 10-60mg (week 1) 60 mg (weeks 2-7) Dose taper (week 8)

PlaceboOTHER

Placebo

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject must have DSM-IV diagnosis of cocaine dependence. * Subject must be seeking treatment for cocaine dependence. * Be be able to verbalize understanding of consent form, provide written consent and verbalize willingness to complete study procedures. Exclusion Criteria: * Please contact site for more information.

Locations (8)

San Francisco General Hosptial

San Francisco, California, United States

Torrance Site

Torrance, California, United States

Denver VA Medical Center

Denver, Colorado, United States

VA Maryland Healthcare System

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

Effects of medication on cocaine craving

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.